focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options - Director/PDMR Shareholding

14 Dec 2022 17:08

RNS Number : 7510J
Evgen Pharma PLC
14 December 2022
 

Evgen Pharma plc

("Evgen" or the "Company")

 

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines announces that, on 14 December 2022, certain employees and directors of the Company, including the following Persons Discharging Managerial Responsibility ("PDMR"), were granted nil cost options (the "Options") over a total of 11,122,199 ordinary shares of 0.25 pence each in the Company ("Ordinary Shares"), exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

 

PDMR

Position

Current Ordinary Shares held

Current Options held

New options granted

% of issued share capital including this award

Dr Huw Jones

CEO

62,500

4,648,890

4,410,727

3.3%

Richard Moulson

CFO

45,454

889,728

1,460,855

 

0.9%

 

The Options will vest on the third anniversary of grant based on performance against challenging

strategic corporate objectives over three years (40%), share price growth (30%) and on an elapsed time basis at 3 years (30%).

 

Following this award there are 21,361,574 options in issue, representing 7.8% of the Company's issued share capital.

 

Enquiries:

Evgen Pharma plcDr Huw Jones, CEO Richard Moulson, CFO 

+44 1625 466591

FinnCap (Nominated Advisor and Broker) Geoff Nash / Teddy Whiley (Corporate Finance)Alice Lane/Nigel Birks (ECM)

+44 20 7220 0500

Instinctif Partners

Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon

+44 207 457 2020Evgen@Instinctif.co

 

 

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Huw Jones

2

Reason for the notification

a)

Position/status

CEO

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma Plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares of 0.25 pence each

 GB00BSVYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

4410727

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 As above

 

 

f)

Date of the transaction

14 December 2022

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Moulson

2

Reason for the notification

a)

Position/status

CFO

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma Plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares of 0.25 pence each

 GB00BSVYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

1460855

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 As above

 

 

f)

Date of the transaction

14 December 2022

g)

Place of the transaction

London Stock Exchange, AIM

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUSRBRUSUUAAA
Date   Source Headline
17th Jun 20207:00 amRNSSFX-01 to be evaluated in COVID-19 trial
15th Jun 20205:05 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSFinal Results
8th Jun 20207:00 amRNSPaper on SFX-01 in ER positive breast cancer
5th Jun 20207:00 amRNSNotice of Results
15th May 202012:30 pmRNSStatement Re: Share Price Movement
30th Apr 20207:00 amRNSDirectorate Change
20th Feb 20209:27 amRNSHolding(s) in Company
13th Feb 20207:00 amRNSUniversity of Rochester Collaboration
6th Feb 20207:00 amRNSUniversity of Manchester collaboration discovery
29th Jan 20202:05 pmRNSSecond Price Monitoring Extn
29th Jan 20202:00 pmRNSPrice Monitoring Extension
20th Jan 20203:39 pmRNSHolding(s) in Company
17th Jan 20203:32 pmRNSHolding(s) in Company
8th Jan 20209:52 amRNSHolding(s) in Company
17th Dec 20197:01 amRNSInvestor presentation
17th Dec 20197:00 amRNSHalf-year Report
5th Dec 20197:00 amRNSMOU with The University of Dundee
4th Dec 20193:11 pmRNSNotice of Results
14th Nov 201911:59 amRNSHolding(s) in Company
11th Nov 201912:11 pmRNSSAS study clarification
11th Nov 20197:00 amRNSSFX-01 results in SAS study
30th Sep 20197:00 amRNSESMO presentation of Phase II STEM clinical data
23rd Sep 20197:00 amRNSUpdate on extended-use phase of STEM trial
5th Sep 20197:00 amRNSAgreement for supply of SFX-01 for autism trial
28th Aug 20197:00 amRNSUpdate on SAS study
7th Aug 20197:00 amRNSGrant of further European patent
5th Aug 20197:00 amRNSResearch collaboration
25th Jul 20191:00 pmRNSGrant of Options
18th Jul 20193:47 pmRNSResult of AGM
18th Jul 20197:00 amRNSAGM Statement
24th Jun 20197:00 amRNSSFX-01 featured in SAH review paper
19th Jun 201910:39 amRNSPosting of Annual Report and AGM Notice
13th Jun 20197:00 amRNSFull Year Results
11th Jun 20197:00 amRNSNotification of Preliminary Results
22nd May 20191:32 pmRNSHolding(s) in Company
21st May 20197:00 amRNSShare Option Exercise and Issue of Equity
9th May 20195:49 pmRNSHolding(s) in Company
9th May 201910:11 amRNSHolding(s) in Company
8th May 201911:29 amRNSResult of GM and Completion of Placing
26th Apr 201911:05 amRNSSecond Price Monitoring Extn
26th Apr 201911:00 amRNSPrice Monitoring Extension
24th Apr 201911:37 amRNSHolding(s) in Company
24th Apr 201911:33 amRNSHolding(s) in Company
23rd Apr 20192:05 pmRNSSecond Price Monitoring Extn
23rd Apr 20192:00 pmRNSPrice Monitoring Extension
23rd Apr 201910:30 amRNSHolding(s) in Company
18th Apr 20195:30 pmRNSPosting of Circular and Timing of General Meeting
17th Apr 20191:00 pmRNSPlacing and Notice of General Meeting
2nd Apr 20199:00 amRNSfinnCap publishes initiation research

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.